GlobeNewswire by notified

AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes

27.10.2026 15:22:24 CET | GlobeNewswire by notified | Press release

Share
  • First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer
  • Advancement follows successful completion of the single ascending dose (SAD) phase, where PATAS was well tolerated with no serious adverse events

STRASBOURG, France, Oct. 27, 2026 (GLOBE NEWSWIRE) -- AdipoPharma, a clinical-stage biotechnology company developing therapies that target adipocyte dysfunction to treat metabolic diseases, today announced the initiation of Phase 1B of its ongoing Phase 1 clinical trial evaluating PATAS. The first participants have been enrolled and dosed in the multiple ascending dose portion of the study, which is being conducted in patients with Type 2 diabetes.

PATAS is a first-in-class insulin sensitizer designed to restore healthy adipose tissue function by re-establishing normal glucose handling in the white adipocyte and subsequently improving whole-body insulin sensitivity. The Phase 1 clinical program is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and pharmacokinetics of PATAS.

“While today’s standard-of-care therapies have made strides in managing glycemic symptoms and weight, directly reversing the underlying cellular driver of insulin resistance remains one of the largest unaddressed markets in cardiometabolic medicine,” said Vincent Marion, MSc., Ph.D., President and CEO of AdipoPharma. “With PATAS, we are pioneering a first-in-class modality designed to restore systemic insulin sensitivity at its source. The favorable safety and tolerability profile demonstrated in our completed Phase 1 single ascending dose study de-risks our clinical foundation and positions us strongly as we advance toward our 2027 data readout with Type 2 diabetic patients.”

A Novel Approach to Type 2 Diabetes

Type 2 diabetes continues to progress and to affect hundreds of millions of people worldwide, driving ongoing demand for therapies that address the underlying causes of the disease. Unlike many therapies that focus primarily on managing the symptoms of Type 2 diabetes, PATAS is designed to address insulin resistance by restoring normal glucose handling in the adipose tissue. AdipoPharma's approach centers on adipocytes, or fat cells, which play a critical role in regulating whole-body insulin sensitivity. “It is important to realize that it is not only the quantity of fat in your body that counts, but also its quality,” said Vincent Marion, MSc., Ph.D., President and CEO of AdipoPharma. When these cells become dysfunctional, systemic insulin resistance is likely to follow, often with detrimental effects throughout the body.

Vincent Marion adds, “As we continue advancing PATAS through clinical development, we look forward to generating the critical data that will help inform the program's future development and potential strategic opportunities.”

About AdipoPharma
AdipoPharma is a clinical-stage biotechnology company pioneering first-in-class, peptide-based therapeutics that target the root cause of insulin resistance, Type 2 diabetes, and related cardiometabolic disorders. By harnessing a deep understanding of adipocyte biology, the company is developing disease-modifying medicines designed to restore physiological glucose uptake and metabolic function directly within fat cells.
www.adipopharma.com.

CONTACT: John Reynolds, john.reynolds@buchananpr.com

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining. Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets. Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining. Sound Money: Discover how tamper-proof currency can enhance stability. Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects. Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bi

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye